Comments*

 
  • Academy News

  • Innovative Funding Models for Alzheimer's Disease & Dementia Research

    One of the many highlights of our Alzheimer's Disease Summit: The Path to 2025, was the panel discussion focused on new and innovative funding models. Watch video highlights from that talk.

    Posted 12/2/2013

    On November 6 and 7, global leaders from government, academia, NGOs, finance, and industry gathered to accelerate progress on Alzheimer's R&D at the "Alzheimer's Disease Summit: The Path to 2025" in NYC. The Summit, co-presented by the New York Academy of Sciences, the Global CEO Initiative on Alzheimer's Disease, and the U.S. National Institute on Aging/NIH, comes during a pivotal time for AD, as the requisite conditions for success in Alzheimer's drug development are converging. Helping drive this momentum, a new report, "Economic Analysis of Opportunities to Accelerate Alzheimer's Research and Development" (pdf) was presented as a working draft to solicit feedback, and summit organizers released a Declaration On Alzheimer's Treatment and Prevention.

    One of the highlight's of the conference's second day was the "Innovative Models of Funding" panel. The talk was moderated by George Vradenburg (The Global CEO Initiative on Alzheimer's Disease), and featured Labeeb M. Abboud, JD (International AIDS Vaccine Initiative/Global Health Investment Fund); Robert J. Appel (Appel Associates); Chas Bountra, PhD (University of Oxford); Surya Kolluri (Bank of America); Henry McCance, MBA (Cure Alzheimer's Fund); Liam O'Neil (Merrill Lynch); Gregory C. Simon, JD (Poliwogg Holdings, Inc.); and Ben Taylor (Goldman Sachs). Watch highlights from their discussion in this video:

    Below are further resources related to the event. And please keep an eye out for an eBriefing about the event which will feature a robust summary and complete media from each panel, along with other resources.

    Program

    Alzheimer's Disease and Dementia Initiative

    The Academy's Alzheimer's Disease and Dementia Initiative (ADDI) aims to accelerate T1 translation — the transfer of basic research about disease mechanisms into the development of new methods for diagnosis, treatment, and prevention — through an unprecedented multi-sector partnership focused on Alzheimer's disease and dementia.

    Archived Event Information

    Alzheimer's Disease Summit: The Path to 2025

    November 6 - 7, 2013
    A primary goal of this critical meeting was to convene leading industry, academic, and government stakeholders to actively participate in discussions regarding how to prevent and effectively treat Alzheimer's by 2025, by coordinating with governmental efforts to build research resources, reengineer current drug development and evaluation systems, and identify innovative technologies and financing models.

    EmailPrint